Context Therapeutics Inc. - CNTX
Ownership (Schedule 13D / 13G) · latest 50 filings
· Back to all files
Visible: 0
| Filed | Form | Reporting person | Percent | Shares | SEC |
|---|---|---|---|---|---|
| May 15, 2026 | SCHEDULE 13G/A | Great Point Partners, LLC | 2.44% | 2,238,496 | View |
| May 15, 2026 | SCHEDULE 13G/A | Dr. Jeffrey R. Jay, M.D. | 2.44% | 2,238,496 | View |
| May 15, 2026 | SCHEDULE 13G/A | Ms. Lillian Nordahl | 2.44% | 2,238,496 | View |
| May 14, 2026 | SCHEDULE 13G | Octagon Capital Advisors LP | 5.7% | 5,250,000 | View |
| May 14, 2026 | SCHEDULE 13G | Octagon Investments Master Fund LP | 5.7% | 5,250,000 | View |
| May 14, 2026 | SCHEDULE 13G | Ting Jia | 5.7% | 5,250,000 | View |
| May 14, 2026 | SCHEDULE 13G/A | Blue Owl Capital Holdings LP | 5.54% | 5,089,015 | View |
| May 12, 2026 | SCHEDULE 13G/A | Avidity Partners Management LP | 8.7% | 8,302,808 | View |
| May 12, 2026 | SCHEDULE 13G/A | Avidity Partners Management (GP) LLC | 8.7% | 8,302,808 | View |
| May 12, 2026 | SCHEDULE 13G/A | Avidity Capital Partners Fund (GP) LP | 8.7% | 8,302,808 | View |
| May 12, 2026 | SCHEDULE 13G/A | Avidity Capital Partners (GP) LLC | 8.7% | 8,302,808 | View |
| May 12, 2026 | SCHEDULE 13G/A | Avidity Private Master Fund I LP | 7.7% | 7,364,795 | View |
| May 12, 2026 | SCHEDULE 13G/A | Michael Gregory | 8.7% | 8,302,808 | View |
| May 08, 2026 | SCHEDULE 13G/A | Soleus Capital Master Fund, L.P. | 7.6% | 6,963,141 | View |
| May 08, 2026 | SCHEDULE 13G/A | Soleus Capital, LLC | 7.6% | 6,963,141 | View |
| May 08, 2026 | SCHEDULE 13G/A | Soleus Capital Group, LLC | 7.6% | 6,963,141 | View |
| May 08, 2026 | SCHEDULE 13G/A | Soleus Capital Management, L.P. | 7.6% | 6,963,141 | View |
| May 08, 2026 | SCHEDULE 13G/A | Soleus GP, LLC | 7.6% | 6,963,141 | View |
| May 08, 2026 | SCHEDULE 13G/A | Guy Levy | 7.6% | 6,963,141 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | MPM BioImpact LLC | 11.6% | 10,679,391 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Great Point Partners, LLC | 5.1% | 4,683,711 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Dr. Jeffrey R. Jay, M.D. | 5.1% | 4,683,711 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Ms. Lillian Nordahl | 5.1% | 4,683,711 | View |
| Feb 03, 2026 | SCHEDULE 13G | Soleus Capital Master Fund, L.P. | 5.2% | 4,776,398 | View |
| Feb 03, 2026 | SCHEDULE 13G | Soleus Capital, LLC | 5.2% | 4,776,398 | View |
| Feb 03, 2026 | SCHEDULE 13G | Soleus Capital Group, LLC | 5.2% | 4,776,398 | View |
| Feb 03, 2026 | SCHEDULE 13G | Soleus Capital Management, L.P. | 5.2% | 4,776,398 | View |
| Feb 03, 2026 | SCHEDULE 13G | Soleus GP, LLC | 5.2% | 4,776,398 | View |
| Feb 03, 2026 | SCHEDULE 13G | Guy Levy | 5.2% | 4,776,398 | View |
Percent = "% of class represented by amount beneficially owned" for this reporting person in the filed 13D/13G.
Shares = reported beneficial ownership amount for the same row (not portfolio shares from 13F).
Amendments (/A) can repeat the same holder over time, so rows should not be summed.
Extraction is best-effort from filing text and can be missing or noisy; verify exact figures via the SEC link in each row.